Autopsy report · NCT03329885

A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis

“Adverse change in the risk/benefit”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 8 months before it stopped.
• 38 participants enrolled.
• Results were posted on the registry 1 year 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Bristol-Myers Squibb

Sponsor type

Industry

Conditions

Rheumatoid Arthritis; Psoriasis; Ankylosing Spondylitis; Inflammatory Bowel Diseases; Nonalcoholic Steatohepatitis

Interventions

BMS-986251; Placebo

Participants

38

Sites

1

Countries

Netherlands

Trials that died the same way

• High Flow Oxygen in Patients Undergoing Suspension Laryngoscopy Under General Anesthesia
  “Risk-benefit analysis” (73% match in meaning)
• A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
  “The benefit-risk profile no longer supports continuing the study” (60% match in meaning)
• Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
  “Other - Adverse Events” (58% match in meaning)
• Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema
  “Adverse Events” (57% match in meaning)
• MB-CART20.1 Melanoma
  “The risk-benefit assessment was not as expected.” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.